Profile data is unavailable for this security.
About the company
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
- Revenue in USD (TTM)0.00
- Net income in USD-139.65m
- Incorporated2017
- Employees112.00
- LocationBiomea Fusion Inc900 Middlefield Road, 4Th FloorREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 980-9099
- Fax+1 (302) 655-5049
- Websitehttps://www.biomeafusion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 295.87m | 13.00 | -- | 1.78 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| PepGen Inc | 0.00 | -89.14m | 299.83m | 64.00 | -- | 1.92 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 300.08m | 168.00 | -- | 0.7843 | -- | 7.40 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 302.62m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -90.69m | 303.36m | 88.00 | -- | 1.57 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 309.00m | 304.00 | -- | 2.03 | -- | 1.82 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 309.83m | 75.00 | -- | 0.6503 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Editas Medicine Inc | 67.03m | -193.45m | 310.94m | 265.00 | -- | 1.34 | -- | 4.64 | -2.36 | -2.36 | 0.8183 | 2.81 | 0.1447 | -- | 52.99 | 252,954.70 | -41.75 | -29.85 | -48.49 | -33.19 | -- | -- | -288.59 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 312.44m | 126.00 | -- | -- | -- | 2.29 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Biomea Fusion Inc | 0.00 | -139.65m | 312.86m | 112.00 | -- | 3.01 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 318.79m | 33.00 | -- | 1.38 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Ocugen Inc | 8.19m | -45.87m | 319.52m | 65.00 | -- | 16.88 | -- | 39.01 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| ADC Therapeutics SA | 66.75m | -214.86m | 321.84m | 273.00 | -- | -- | -- | 4.82 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| MeiraGTx Holdings PLC | 8.12m | -93.14m | 322.63m | 387.00 | -- | 3.38 | -- | 39.72 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Personalis Inc | 80.03m | -81.45m | 325.44m | 223.00 | -- | 2.71 | -- | 4.07 | -1.63 | -1.63 | 1.59 | 2.12 | 0.3683 | 6.68 | 6.94 | 358,865.50 | -37.49 | -28.84 | -43.81 | -34.72 | 27.76 | 28.65 | -101.78 | -96.01 | 3.05 | -- | 0.0199 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| Poseida Therapeutics Inc | 88.46m | -112.77m | 327.30m | 337.00 | -- | 5.38 | -- | 3.70 | -1.19 | -1.19 | 0.9296 | 0.6265 | 0.3051 | -- | 7.27 | 268,066.70 | -38.89 | -40.70 | -52.75 | -47.72 | -- | -- | -127.48 | -233.49 | -- | -13.14 | 0.4916 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
Data as of Sep 20 2024. Currency figures normalised to Biomea Fusion Inc's reporting currency: US Dollar USD
49.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.39m | 14.89% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 3.57m | 9.86% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 2.11m | 5.82% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.00m | 5.52% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.32m | 3.64% |
| Adage Capital Management LPas of 30 Jun 2024 | 1.10m | 3.04% |
| Aisling Capital Management LPas of 30 Jun 2024 | 798.76k | 2.21% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 675.74k | 1.87% |
| Geode Capital Management LLCas of 30 Jun 2024 | 597.19k | 1.65% |
| Point Sur Investors LLCas of 31 Dec 2023 | 480.79k | 1.33% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
